Opinion|Videos|January 16, 2025
Building Physician-Patient Trust to Increase Timely Screening Rates
Author(s)Kameelah Phillips, MD, FACOG, NCMP
Kameelah Phillips, MD, FACOG, NCMP, discusses how health care providers (HCPs) can empower patients to advocate for their health during cervical cancer and sexually transmitted infection (STI) screenings by building trust, fostering open communication about sensitive topics, and striking a balance between sensitivity and thorough screening practices.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What steps can HCPs take to help educate and build the confidence of their patients to advocate for their own health during visits focused on cervical cancer and STI screenings?
- How can HCPs build a trusting relationship with their patients to facilitate open discussions about sensitive topics like cervical cancer and STI screenings?
- How can HCPs balance the need for sensitivity with the importance of thorough screening practices?
Advertisement
Related to this article
Chrisandra Shufelt, MD, on using a cardiovascular risk score to guide hormone therapy candidacy at menopause.
The October 30 update from the FDA follows the February 12, 2026 labeling changes to 6 menopausal hormone therapy products in which the agency also removed safety-related boxed warnings.
Neither maternal MOUD dose nor umbilical cord opioid levels were associated with neonatal opioid withdrawal syndrome severity.
Susan Reed, MD, on the need for menopause research funding, a clinical trials network, and studies in understudied groups and perimenopause.
Chrisandra Shufelt, MD, on why menopause is a window for cardiovascular prevention and the risk factors OB/GYNs should assess.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
ACOG advises against GLP-1 receptor agonists in pregnancy and recommends considering discontinuation 1 to 2 months before conception.
Rhonda Voskuhl, MD, on a case series in which estriol and progesterone improved self-reported cognition in menopausal women at 12 months.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
ACOG advises against GLP-1 receptor agonists during pregnancy
2
FDA removes boxed warnings from 3 more menopausal hormone therapy products
3
Matthew Nudy, MD, on estrogen and the cardiovascular system
4
Safety Monitoring and Dosing for NK3 Antagonists in Menopause VMS
5